Connect Biopharma Holdings Limited
CNTB
NASDAQ·Healthcare·Biotechnology·Mkt cap $148.6M
$2.36
▲ +7.27%
P/E
-5.81
Mkt Cap
$148.6M
52-Wk Range
$1.23–$3.82
52-Week Range
$1.23 - $3.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 11.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in specific immune modulation pathways with limited competitive overlap
- Multiple shots on goal with diversified pipeline across different therapeutic mechanisms
- Experienced management team with deep immunology and clinical development expertise
- Strategic positioning in high-value autoimmune and allergic disease markets
Bear Case
1 risk
- Low volatility (beta -0.2).
Growth
Stable outlook
Phase IIb clinical trial progression of lead candidate CBP-201 with potential positive data readouts
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+9.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CNTB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.27 vs -$0.31 consensus (+14.3% surprise). Revenue of $2.7M vs $743.3K expected (+269.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+14.3%
Revenue trend · last 8Q
—
—
—
—
—
-100%
-100%
-100%
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
Q4 25
Q2 26
$0
$0
$0
$3.6M
$103.1K
$7.1K
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Jun 26, 2026
vs Industry
How CNTB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related